Site icon pharmaceutical daily

What 141 HIV/AIDS Patient Groups Thought of 9 Pharma Companies in 2019 | Survey Findings Report 2020 – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “The Corporate Reputation of Pharma in 2019 – The Patient Perspective – HIV/AIDS Edition – The Views of 141 HIV/AIDS Groups” report has been added to ResearchAndMarkets.com’s offering.

This is the 7th edition of the report series. The 2019 results are drawn from a survey of HIV/AIDS patient groups, conducted November 2019 – February 2020.

About the 2019 survey of HIV/AIDS patient groups

On HIV/AIDS patient-group relationships with pharma

What this Report Contains

Industry-wide analyses: The report examines the issues of importance to HIV/AIDS patient groups, including: levels of industry innovation; access to treatments; transparency of the industry; and drug pricing. Analyses are reinforced by extensive feedback from 2019’s respondent HIV/AIDS patient groups [found in Appendix I], organised according to the country headquarters of the respondent patient groups.

Individual company analyses: The 9 pharma companies are reviewed by 2019’s 141 respondent HIV/AIDS patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation.

(Read more…)

Key Industry-Wide Findings

In 2019, HIV/AIDS patient groups took a more negative view of the corporate reputation of the pharmaceutical industry, compared with patient organisations of other specialties. Some 39% of 2019’s 141 respondent HIV/AIDS patient groups thought that the pharma industry had an Excellent or Good corporate reputation, ranking pharma 3rd out of nine healthcare sectors. The equivalent figure reported by patient groups worldwide was 46% – ranking pharma 1st.

HIV/AIDS patient groups nominated generic drug manufacturers as 1st in 2019, with 49% of the HIV/AIDS patient groups describing that sector’s corporate reputation as Excellent or Good. These results probably reflect the ongoing concerns that HIV/AIDS advocacy groups have with the pricing arrangements of prophylactic drugs (for the prevention of HIV transmission, and the treatment of HIV/AIDS). Advocates argue that the unnecessary maintenance of high prices has led to profound health inequalities.

The Thailand-based Asia Pacific Council of AIDS Service Organizations (APCASO) defines how pharmaceutical companies could improve, and be more patient centric: Shift the approach by treating anyone desperate to return to health as people, and not patients. If they can do that, and come down to the ground to understand the real value of the drugs they manufacture on the lives and livelihood of people, they will be more likely to connect with the individuals through whom they will likely make a profit. Building a business model that protects the beneficiaries of your products is not a difficult one to see and make with a person-centred approach.

On the quality of pharma products: The majority of HIV/AIDS patient groups responding to the ‘2019 Corporate-Reputation’ survey clearly believed that the pharmaceutical industry is adept at making products of benefit to patients. As many as 66% of 2019’s 141 respondent HIV/AIDS patient groups stated that the pharma industry was Excellent or Good at this activity. The equivalent figure for 2018’s HIV/AIDS respondents was 57%. In July 2019, renewed efforts to develop a HIV vaccine were announced at the 10th International AIDS Society Conference on HIV Science.

On drug pricing: The 2019 survey found the main areas of discord between HIV/AIDS patient groups and pharma to be drug pricing and access to medicines. As in previous years (and in common with patient groups of other therapy areas), the vast majority of 2019’s respondent HIV/AIDS patient groups rated the industry low for transparency in pricing, and low for having fair pricing policies – with just a minority (12%) calling the industry Excellent or Good at either. The resentment is tangible; one local US-based HIV/AIDS group noted: Predatory pricing is rampant in the industry. Often, it’s insidious – taking annual incremental price increases on long-approved drugs, increasing the overall cost of healthcare.

Just 30% of 2019’s 141 respondent HIV/AIDS patient groups stated that the industry was Excellent or Good at ensuring access to medicines. Although the figure is low, most patient groups from other therapy areas ranked the pharma industry lower still for this measure.

Key Company Findings

A note about COVID-19 and this study’s results

COVID-19 should have a relatively limited impact on many of the results of the 2019 Corporate-Reputation’ study, because the survey took place (November 2019 to late-February 2020) largely before the crisis became global. However, announcements about COVID-19 by some pharma companies during January and February 2020, may have influenced the views of patient groups responding to the ‘Corporate-Reputation’ survey during its last two months.

Key Topics Covered

Profiles of the 9 companies, 2019 v. 2018, charts and tables

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/hr71w3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version